CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Protalix Biotherapeutics, Inc.  (PLX)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
 
 

PLX's Revenue Year on Year Growth by Quarter and Year

Protalix Biotherapeutics,'s Revenue results by quarter and year



Select the Comparisons : Select the Ratio:                        
PLX Revenue (in millions $) FY 2017 FY 2016 FY 2015 FY 2014
IV Quarter December - 2.08 -9.66 2.13
III Quarter September - 4.67 5.85 2.40
II Quarter June - 1.77 3.78 2.43
I Quarter March 2.89 0.68 4.39 6.70
FY   2.89 9.20 4.36 13.66

Financial Statements
Protalix Biotherapeutics,'s first quarter 2017 Revenue $ 2.89 millions PLX's Income Statement
Protalix Biotherapeutics,'s first quarter 2016 Revenue $ 0.68 millions Quarterly PLX's Income Statement
PLX's Growth by Division See PLX's Growth by Segment

PLX Revenue ( Y/Y Growth %) 2017
2016 2015 2014
IV Quarter December - - - -9.75 %
III Quarter September - -20.17 % 143.75 % 5.26 %
II Quarter June - -53.17 % 55.56 % 7.52 %
I Quarter March 324.85 % -84.51 % -34.48 % 87.68 %
FY   - 111.01 % -68.08 % -



PLX Revenue Growth Comment
Protalix Biotherapeutics, Inc. achieved in the first quarter, above Company average Revenue surge of 324.85% year on year, to $ 2.89 millions.

Looking into first quarter results within Biotechnology & Drugs industry 6 other companies have achieved higher Revenue growth. While Protalix Biotherapeutics, Inc.' s Revenue doubling of 324.85% ranks overall at the positon no. 91 in the first quarter.



Revenue Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #7
Healthcare Sector #25
S&P 500 #91
Revenue Y/Y Growth Statistics
High Average Low
325.48 % 25.81 % -91.33 %
(Mar 31 2017)   (Jun 30 2013)

You need to upgrade your Flash Player

Other Revenue Growth
Biotechnology & Drugs Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PLX's Revenue Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for PLX's Competitors
Revenue Growth for Protalix Biotherapeutics,'s Suppliers
Revenue Growth for PLX's Customers

You may also want to know
PLX's Annual Growth Rates PLX's Profitability Ratios PLX's Asset Turnover Ratio PLX's Dividend Growth
PLX's Roe PLX's Valuation Ratios PLX's Financial Strength Ratios PLX's Dividend Payout Ratio
PLX's Roa PLX's Inventory Turnover Ratio PLX's Growth Rates PLX's Dividend Comparisons



Companies with similar Revenue doubling for the quarter ending Mar 31 2017 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2017
Geovax Labs, Inc.  521.29 %$ 521.292 millions
Cytomx Therapeutics, Inc.  424.20 %$ 424.202 millions
Sientra, Inc.  409.11 %$ 409.109 millions
Sorrento Therapeutics, Inc.  393.32 %$ 393.320 millions
Bluebird Bio, Inc.  355.77 %$ 355.771 millions
Agenus Inc  352.36 %$ 352.365 millions
Protalix Biotherapeutics, Inc.  325.48 %$ 325.479 millions
Lifestyle Medical Network, Inc.  319.44 %$ 319.438 millions
Orexigen Therapeutics, Inc.  280.39 %$ 280.389 millions
Intellia Therapeutics, Inc.  249.75 %$ 249.747 millions
Biolargo, Inc.  230.06 %$ 230.060 millions
Corbus Pharmaceuticals Holdings, Inc.  226.20 %$ 226.199 millions
Exact Sciences Corp  226.01 %$ 226.006 millions
Accelerate Diagnostics, Inc.  225.15 %$ 225.153 millions
American Cryostem Corp  205.95 %$ 205.946 millions
Ionis Pharmaceuticals Inc  199.14 %$ 199.138 millions
Immune Design Corp.  193.34 %$ 193.344 millions
Transgenomic Inc  178.81 %$ 178.814 millions
Icu Medical Inc  175.71 %$ 175.710 millions
Novocure Ltd  167.22 %$ 167.218 millions


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2017 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com